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Introduction
Methods
Results	
After	a	spinal	cord	injury,	a	lesion	forms	at	the	site	of	
injury	which	inhibits	the	regeneration	of	axons. Drs.	Ann	
Parr	and	Michael	McAlpine	currently	have	a	collaborative	
grant	to	develop	a	3D	bioprinted,	customizable	spinal	cord	
scaffold	loaded	with	motor	neuron	progenitor	cells	
(MNPCs)	that	can	be	inserted	in	this	lesion	as	a	potential	
treatment	for	spinal	cord	injury.	Previously,	the	lab	has	
used	gelatin	methacrylate	(GELMA)	and	Matrigel,	a	murine	
Engelbreth-Holm-Swarm	(EHS)	sarcoma	extract	as	
potential	bioinks.	Gelma	is	believed	to	produce	free	
radicals	during	the	photo-polymerization	step	of	
bioprinting,	resulting	in	low	cell	viability.	Matrigel	is	
composed	of	poorly	controlled	mixtures	of	growth	factors	
and	basement	membrane	proteins.	Batch	to	batch	
variation	of	Matrigel	leads	to	inconsistent	3D	bioprinting	
settings	and	thus,	a	fully	defined	bioink	that	results	in	high	
viability	of	MNPCs	must	be	developed.	
Conclusions
Prior	to	the	production	of	fibrinogen-based	bioink,	a	bank	
of	MNPCs	derived	from	human	induced	pluripotent	stem	
cells	(hIPSC)	was	produced	using	a	protocol	developed	in	
the	Parr	lab.	Different	variations	of	fibrinogen-based	
bioinks	were	then	prepared	based	on	previous	work	by	
Lewis	et	al.	and	Atala et	al.	The	Primary	components	of	
these	bioinks	include	fibrinogen,	gelatin,	glycerol,	and	
hyaluronic	acid.	MNPCs	were	them	suspended	into	each	
bioink	and	plated.	The	bioink	which	resulted	in	highest	
overall	cell	viability	was	sent	to	printing.	The	cell-laden	
bioink	was	then	printed	into	3D	scaffolds.	Cell	viability	was	
again	assessed	to	determine	cell	viability	following	the	3D	
bioprinting	process.	Using	immunohistochemistry,	
differentiation	of	MNPCs	was	assessed	after	the	addition	
of	multiple	growth	factors.	The	final	fibrinogen	bioink	
composition	consisted	of	10	mg/mL	fibrinogen,	7.5	
wt/vol%	gelatin,	2.5	mM CaCl2,	and	3	mg/mL	HA.	These	
components	were	diluted	from	stock	solution	using	
either	DMEM	basal	media	or	N2B27	growth	media.	
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In	conclusion,	a	fibrinogen-based	bioink	was	developed	based	on	previous	literature	that	is	capable	of	promoting	viability	
and	differentiation	of	MNPCs	when	plated	before	the	printing	process.	However,	when	plating	MNPCs	after	the	printing	
process,	viability	and	differentiation	are	greatly	reduced,	indicating	that	the	printing	process	itself	is	adversely	affecting	the	
viability	and	differentiation	of	these	cells	and	that	this	process	needs	optimization	before	moving	forward.
MNPC	2D	culture	viability	pre-printing	process. MNPC	2D	culture	viability	post-printing	process	in	modified	fibrinogen-based	bioinks.
